KNSA.NASDAQ
- Kiniksa Pharmaceuticals International plc
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.15/--
|
企業價值
1.65B
|
資產負債 |
每股賬面淨值
6.11
|
現金流量 |
現金流量率
0.02
|
損益表 |
收益
270.26M
|
每股收益
3.49
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/10/31 19:25 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |